LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply
AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.
—
Filed today
—
Companies tracked
NSE & BSE
Listed on
👋Welcome back, there — you're tracking 0 companies
🔔Sign in free to track companies and get alerts the moment they file
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors
Latest Filings —
📋 Filing Types Available on ForgeUp Filings
Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
A court has approved plans for one Kopran company to merge into another; shareholders and creditors must now vote on the deal.
🤖 AI Summary
NCLT Mumbai bench issued merger approval order dated April 09, 2026 for Kopran Laboratories absorption into Kopran Limited
Order directs equity shareholders, secured creditors, unsecured creditors meetings to be convened by both companies
Merger scheme filed March 20, 2025; NCLT approval clears regulatory pathway for shareholder voting stage
Scheme of Amalgamation structured under Companies Act 2013 Sections 230-232; completion subject to shareholder and creditor approvals
🔢 Key Numbers — exact figures from BSE filing, not rounded
NCLT Order Date
April 09, 2026
Scheme Filed
March 20, 2025
BSE Scrip Code
524280
🏢 How This Affects the Company
📈
Business Impact
Merger consolidation will combine Kopran Laboratories operations into the parent Kopran Limited entity, eliminating duplicate corporate structure and streamlining business activities post-approval.
💰
Financial Impact
Post-merger balance sheets will consolidate; no financial terms disclosed in filing. Shareholder value impact depends on merger consideration and final court sanction.
⚙️
Operational Impact
Consolidated entity will eliminate duplication between parent and subsidiary operations, integrate workforce and facilities, and streamline governance under single company structure.
⚠️
Risk Impact
Shareholder and creditor approval is not assured. Delays in voting meetings or rejection of scheme by either group halt the merger. Regulatory conditions remain pending.
👥 What This Means For Shareholders
✅
Action Required
Shareholders of both Kopran Limited and Kopran Laboratories must review merger scheme details and participate in upcoming shareholder meetings when called.
👤
Who Is Affected
All equity shareholders of both companies will vote on merger scheme. Consideration terms determine value impact per share held, though no exchange ratio is disclosed in this filing.
🔍
Management Signal
Management has pursued formal merger pathway through NCLT, indicating commitment to corporate consolidation and parent-subsidiary integration as strategic objective.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Shareholder meeting notice and voting date — check BSE filings and company website for meeting schedule within 30 days.
Secured and unsecured creditor meeting outcomes — track approval percentages required and voting timelines from NCLT order details.
Final court sanction order — watch for Reg 37 filing once shareholder vote is complete; required for merger effectiveness.
MEDIUM RISKShareholder approval not assured. Creditor opposition or voting rejection halts merger. No consideration terms disclosed; valuation risk unclear to shareholders.
💡 Investor Takeaway
NCLT has cleared the merger scheme for Kopran Laboratories into Kopran Limited under Companies Act Sections 230-232. Shareholder and creditor voting meetings must now be held. Court approval is a necessary but not sufficient condition — deal completion requires positive votes and final court sanction.
⚖️ Strengths & Concerns
✅ Positives
NCLT regulatory approval obtained — court found scheme meets statutory requirements and public interest tests under Companies Act.
Clear procedural pathway established — order specifies meetings timeline and stakeholder voting process removes uncertainty on next steps.
⚠️ Concerns
Shareholder and creditor approval not yet secured — merger cannot proceed without positive votes from both equity and debt holder groups.
No merger consideration or exchange ratio disclosed — shareholders voting without clear understanding of value received per share.
📅 Company Track Record
Kopran Limited incorporated 1958 (CIN L 24230 MH 1958 PLC 011078). No prior BSE filings provided for comparison. Company operates pharmaceutical manufacturing with facilities in Raigad district. Kopran Laboratories Limited is subsidiary being merged; consolidation is parent-driven corporate restructuring.
Based on publicly available historical data. For context only.
There are 32,000 more, and one of them is about a company you own
Follow a company and we'll email you the moment it files
again — explained, not just forwarded. Free.
Follow companies and get filings by email
Save any filing to read later
Two full AI analyses every month, free
No card needed. Sign in with Google in two taps.
⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔖
Save filings you care about
Sign in free to save any filing and get notified when the same company files again.
🔖
Save This Filing
Sign in with Google to save this filing and get notified when this company files again. Free, takes 5 seconds.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.